CollaGenex Pharmaceuticals Announces First Quarter 2001 Conference Call

Apr 19, 2001, 01:00 ET from CollaGenex Pharmaceuticals, Inc.

    NEWTOWN, Pa., April 19 /PRNewswire/ -- CollaGenex Pharmaceuticals, Inc.
 (Nasdaq:   CGPI), today announced that it will hold a conference call on
 Tuesday, April 24, 2001, at 11:00 a.m. Eastern Time to discuss first quarter
 results.  The call can be accessed via the Internet through www.collagenex.com
 or www.streetevents.com .  The conference call will be available for replay on
 both websites for a period of 90 days.
 
     About the Company
     CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company
 focused on providing innovative medical therapies to the dental market.  The
 company's lead product, Periostat(R), was approved by the FDA in September
 1998 and is the first and only pharmaceutical to treat periodontal disease by
 inhibiting the enzymes that destroy periodontal support tissues.  Periostat is
 marketed to the dental community by CollaGenex through a professional
 pharmaceutical sales force composed of approximately 135 sales representatives
 and managers.  Currently, the company's dental sales force is also marketing
 Vioxx, a Merck & Co. drug that the company co-promotes for the treatment of
 acute dental pain.
 
     To receive additional information on the Company, please visit our Web
 site at www.collagenex.com , which is not a part of this press release.
 
 

SOURCE CollaGenex Pharmaceuticals, Inc.
    NEWTOWN, Pa., April 19 /PRNewswire/ -- CollaGenex Pharmaceuticals, Inc.
 (Nasdaq:   CGPI), today announced that it will hold a conference call on
 Tuesday, April 24, 2001, at 11:00 a.m. Eastern Time to discuss first quarter
 results.  The call can be accessed via the Internet through www.collagenex.com
 or www.streetevents.com .  The conference call will be available for replay on
 both websites for a period of 90 days.
 
     About the Company
     CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company
 focused on providing innovative medical therapies to the dental market.  The
 company's lead product, Periostat(R), was approved by the FDA in September
 1998 and is the first and only pharmaceutical to treat periodontal disease by
 inhibiting the enzymes that destroy periodontal support tissues.  Periostat is
 marketed to the dental community by CollaGenex through a professional
 pharmaceutical sales force composed of approximately 135 sales representatives
 and managers.  Currently, the company's dental sales force is also marketing
 Vioxx, a Merck & Co. drug that the company co-promotes for the treatment of
 acute dental pain.
 
     To receive additional information on the Company, please visit our Web
 site at www.collagenex.com , which is not a part of this press release.
 
 SOURCE  CollaGenex Pharmaceuticals, Inc.